TY  - BOOK
AU  - Baker, Nevin C
AU  - Lhermusier, Thibault
AU  - Lipinski, Michael J
AU  - Waksman, Ron
TI  - Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar
SN  - 0009-7322
PY  - 2014///
KW  - *Acute Coronary Syndrome/pc [Prevention & Control]
KW  - *Drug Approval
KW  - *Lactones/tu [Therapeutic Use]
KW  - *Plaque, Atherosclerotic/pc [Prevention & Control]
KW  - *Platelet Aggregation Inhibitors/tu [Therapeutic Use]
KW  - *Pyridines/tu [Therapeutic Use]
KW  - Clinical Trials Data Monitoring Committees
KW  - Hemorrhage/ep [Epidemiology]
KW  - Humans
KW  - Lactones/ae [Adverse Effects]
KW  - Platelet Aggregation Inhibitors/ae [Adverse Effects]
KW  - Pyridines/ae [Adverse Effects]
KW  - Receptor, PAR-1/ai [Antagonists & Inhibitors]
KW  - Risk Assessment
KW  - United States
KW  - MedStar Heart & Vascular Institute
KW  - Congresses
N1  - Available online from MWHC library: 1950 - present, Available in print through MWHC library: 1999 - 2006
UR  - http://dx.doi.org/10.1161/CIRCULATIONAHA.114.011471
ER  -